Skip to main content
Clinical Trials/NCT03527277
NCT03527277
Completed
Not Applicable

The Effects of Orange Juice Compared With Sugar-sweetened Beverage on Risk Factors and Metabolic Processes Associated With the Development of Cardiovascular Disease and Type 2 Diabetes

University of California, Davis1 site in 1 country56 target enrollmentStarted: June 1, 2018Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
56
Locations
1
Primary Endpoint
Fasting Low Density Lipoprotein Cholesterol (LDL-C)

Overview

Brief Summary

The objectives of this proposal are to address the gaps in knowledge regarding the metabolic effects of consuming orange juice, the most frequently consumed fruit juice in this country, compared to sugar-sweetened beverage.

Detailed Description

Specific Aims: There is considerable epidemiological evidence that demonstrates associations between added sugar/sugar-sweetened beverage consumption and increased risk for or prevalence of chronic diseases such as cardiovascular disease (CVD), type 2 diabetes (T2D), metabolic syndrome, and gout. Especially concerning is recent evidence from National Health and Nutrition Examination Survey III that demonstrates that there is increased risk of CVD mortality with increased intake of added sugar across quintiles (Yang, 2014). Even the US mean added sugar intake, 15% of daily calories, was associated with an 18% increase in risk of CVD mortality over 15 years. The results from the investigator's recently completed study (1R01 HL09133) corroborate these findings (Stanhope, 2015). They demonstrate that supplementing the ad libitum diets of young adults with beverages containing 0, 10, 17.5 or 25% of daily energy requirement (Ereq) as high fructose corn syrup (HFCS) affects lipid/lipoprotein risk factors for CVD in a dose response manner. Specifically, levels of nonHDL-cholesterol(C), LDL-C, apolipoprotein B (apoB), and postprandial triglycerides (TG) increased linearly over a 2-week period with increasing doses of HFCS. Furthermore, even the participants consuming the 10% Ereq dose exhibited increased levels of these risk factors compared to baseline.

These and similar results have helped to lead to reductions in soda consumption in this country, and new dietary guidelines and FDA food labeling requirements to promote reductions in added sugar consumption. However, there are gaps in knowledge about other sugar-containing foods that lead to public confusion concerning healthier options for soda, and impede further progress in implementing public health policies that will promote further reductions in soda consumption. One such food is naturally-sweetened fruit juice. The amount of sugar in fruit juice is comparable to the amount in soda. Because of this, a consumer seeking answers on the internet will find many articles in which experts state or suggest that the effects of consuming fruit juice are as detrimental as or even worse than those of soda. However, in contrast to soda, fruit juice contains micronutrients and bioactives that may promote health. Therefore the consumer can also find numerous articles on the internet where the health benefits of fruit juice and these bioactives are extolled. There are a limited number of clinical dietary intervention studies that have directly compared the metabolic effects of consuming fruit juice and sugar-sweetened beverage, and their results are not conclusive. Thus we will pursue the following Specific Aims:

  1. Specific Aim 1: To compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages for 4 weeks on risk factors for CVD and other chronic disease in normal weight and overweight men and women.
  2. Specific Aim 2: To mechanistically compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages on metabolic processes associated with the development of CVD and T2D in normal weight and overweight men and women.
  3. Specific Aim 3: To relate the changes assessed under Specific Aims 1 and 2 to the changes in the urinary levels of metabolites and catabolites of the main flavanones in orange juice, hesperetin and naringenin.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
Single (Outcomes Assessor)

Masking Description

All outcomes will be analyzed/assessed by subject identity number, which are assigned prior to randomization to experimental arm.

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • men and pre-menopausal women Body mass index: 20-35 kg/m2 Body weight \> than 50 kg Self-reported stable body weight during the prior six months

Exclusion Criteria

  • Fasting glucose \>125 mg/dl Evidence of liver disorder (AST or ALT \>200% upper limit of normal range) Evidence of kidney disorder (\>2.0 mg/dl creatinine) Evidence of thyroid disorder (out of normal range) Systolic blood pressure consistently over 140 mmHg or diastolic blood pressure over 90 mmHg Triglycerides \> 400 mg/dl LDL-C \> 160 mg/dl in combination with Chol:HDL \> 4 Hemoglobin \< 10 g/dL Pregnant or lactating women Current, prior (within 12 months), or anticipated use of any hypolipidemic or anti-diabetic agents.
  • Use of thyroid, anti-hypertensive, anti-depressant, weight loss medications or any other medication which, in the opinion of the investigator, may confound study results Use of tobacco Strenuous exerciser (\>3.5 hours/week at a level more vigorous than walking) Surgery for weight loss Diet exclusions: Food allergies, special dietary restrictions, routine consumption of less than 3 meals/day, routine ingestion of more than 2 sugar-sweetened beverages or 1 alcoholic beverage/day, unwillingness to consume any food on study menu Veins that are assessed by the R.N.s as being unsuitable for long-term infusions and multiple blood draws from a catheter.
  • Pre-existing claustrophobia or metal implants that preclude magnetic resonance imaging Any other condition that, in the opinion of the investigators, would put the subject at risk

Outcomes

Primary Outcomes

Fasting Low Density Lipoprotein Cholesterol (LDL-C)

Time Frame: 4 weeks

Absolute change of plasma LDL-C concentration (4 week value - 0 week value)

Postprandial Low Density Lipoprotein Cholesterol (LDL-C)

Time Frame: 4 weeks

Absolute change of plasma postprandial LDL-C concentration (4 week value - 0 week value)

Fasting Apolipoprotein B (apoB)

Time Frame: 4 weeks

Absolute change of plasma apoB concentration (4 week value - 0 week value)

Postprandial Apolipoprotein B (apoB)

Time Frame: 4 weeks

Absolute change of plasma postprandial apoB concentration (4 week value - 0 week value)

Fasting Uric Acid

Time Frame: 4 weeks

Absolute change of plasma uric acid concentration (4 week value - 0 week value)

Postprandial Uric Acid

Time Frame: 4 weeks

Absolute change of post-dinner 4-hour AUC plasma uric acid concentration (4 week value - 0 week value)

Fasting Apolipoprotein CIII (apoCIII)

Time Frame: 4 weeks

Absolute change of fasting plasma apoCIII concentration (4 week value - 0 week value)

Postprandial Apolipoprotein CIII (apoCIII)

Time Frame: 4 weeks

Absolute change of plasma postprandial apoCIII concentration (4 week value - 0 week value)

Postprandial Triglyceride

Time Frame: 4 weeks

Absolute change of 4-h post-dinner AUC plasma triglyceride concentration (4 week value - 0 week value)

Hepatic Triglyceride

Time Frame: 4 weeks

Absolute change of % hepatic triglyceride (4 week value - 0 week value)

Matsuda Insulin Sensitivity Index (ISI)

Time Frame: 4 week

Absolute change of Matsuda ISI (4 week value - 0 week value). The Matsuda Index is a ratio of glucose and insulin levels during oral glucose tolerance test. It is calculated using fasting and mean glucose and insulin measurements, but the units of these measurements cancel out in the formula. A Matsuda value less than 2.5 may indicate insulin resistance, thus a lowering of the Matsuda index is a detrimental outcome. At baseline the Matsuda index in the participants for which it was assessed ranged from 1.4 to 7.8 (mean = 3.7, standard deviation = 1.6).

Postprandial de Novo Lipogenesis

Time Frame: 4 weeks

Absolute change of 8-hour area under the curve (AUC) percentage fractional rate postprandial de novo lipogenesis DNL (4 week value - 0 week value)

M Value During Hyperinsulinemic Euglycemic Clamp

Time Frame: 4 weeks

Absolute change of M value (glucose infusion rate during final 30 minute steady state)/ fat free body mass (kg) (4 week value - 0 week value)

Secondary Outcomes

  • Oral Glucose Tolerance Test (OGTT) Glucose 3-hour Area Under the Curve (AUC)(4 week)
  • Oral Glucose Tolerance Test (OGTT) Insulin 3-hour Area Under the Curve(4 week)
  • p-Hydroxyhippuric Acid(4 weeks)
  • 3-(4'-Methoxyphenyl)Propionic Acid-3'-O-glucuronide(4 weeks)
  • Hesperetin-7-O-glucuronide(4 weeks)
  • Naringin-7-O-glucuronide(4 weeks)
  • Fasting Triglyceride(4 weeks)
  • 3-(3'-Hydroxy-4'-Methoxyphenyl)Hydracrylic(4 weeks)
  • Hesperetin-3'-O-glucuronide(4 weeks)
  • Hesperetin-3',7-0-diglucuronide(4 weeks)
  • Fasting de Novo Lipogenesis(4 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Kimber Stanhope

Research Nutritional Biologist

University of California, Davis

Study Sites (1)

Loading locations...

Similar Trials